The Jade Award recognizes companies that weave sustainability into their core strategy, governance, and long-term value creation. For WuXi Biologics, the accolade highlights an integrated four-tier governance structure overseen by an ESG Committee, which embeds environmental and social responsibility into daily operations. CEO Dr. Chris Chen emphasized that these practices are central to the company’s mission of supporting global partners while advancing green solutions across the biologics lifecycle.
WuXi Biologics Claims Top Sustainability Honors at The Asset Awards 2026
WuXi Biologics has secured the prestigious Jade Award at The Asset Corporate Sustainability Leadership Awards 2026, distinguishing itself as the sole pharmaceutical company to achieve the program’s highest honor. The organization also received the Best in Transition (Hong Kong) title, marking a significant milestone in its ongoing green and digital transformation.
Beyond this recent recognition, the company maintains a strong international profile in sustainability rankings, holding an MSCI AAA rating and a Platinum Medal from EcoVadis. Its commitment to a "Green CRDMO" model utilizes renewable energy and digital management platforms to improve resource efficiency. By merging data-driven decision-making with environmental stewardship, the firm continues to align its research, development, and manufacturing processes with global standards for responsible industry growth.
Comments (0)
No comments yet. Be the first!